GLOBAL HOME INFUSION THERAPY MARKET (2026  2030)

In 2025, the global Home Infusion Therapy Market was valued at approximately USD 41.97 billion. It is projected to grow at a CAGR of around 7.47% during the forecast period of 2026–2030, reaching an estimated USD 60.18 billion by 2030.

Home infusion therapy is defined as the administration of biologics, nutrients, medications, or fluids via intravenous or subcutaneous routes within a patient’s home environment. It encompasses a range of treatments, including antibiotics, chemotherapy, parenteral nutrition, and pain management, delivered using infusion pumps, catheters, and related devices under the oversight of qualified healthcare professionals. This model functions as a substitute for inpatient care by minimizing hospital stays, reducing overall treatment expenses, and improving patient comfort and convenience. By limiting reliance on hospital infrastructure and extended admissions, home infusion contributes to meaningful cost efficiencies. Consequently, both payers and healthcare providers are increasingly adopting home-based care models to enhance economic outcomes while maintaining care quality.

Market expansion is supported by multiple factors, including a growing geriatric population with limited mobility, increasing patient preference for home-based care, and rapid technological progress in infusion systems. Infusion therapies, including intravenous (IV) therapy and IV hydration, are critical in managing conditions such as immune disorders, cancer, and congestive heart failure, particularly where oral treatments are ineffective. The rising need for long-term therapeutic interventions further strengthens demand, positioning home infusion as a cost-efficient alternative to hospital-based treatment. The integration of IV therapy and hydration solutions also improves access to personalized and effective care, enabling patients to receive treatment safely and conveniently within their home setting.

Key Market Insights

1. Infusion therapy is emerging as a rapidly expanding segment within the healthcare ecosystem, supported by ongoing drug innovation and increased utilization rates. The growing prevalence of chronic conditions, including cancer, gastrointestinal disorders, and immune deficiency diseases, combined with an aging population and continuous technological advancements, is expected to sustain strong demand for infusion-based treatments.
2. The delivery of infusion therapy is progressively shifting beyond traditional hospital environments to alternative care settings such as physician offices, ambulatory infusion centers, and patient homes. This transition has attracted significant interest from private equity investors, who recognize these evolving care models as high-growth opportunities within an already established market.
3. The expansion of care-at-home models presents value creation opportunities across multiple stakeholders, including payers, healthcare providers, physician groups, home care organizations, technology firms, and investors. In addition to economic benefits, this approach enhances patient experience and overall quality of care by enabling treatment in a more convenient and familiar environment.
4. The home infusion therapy market is primarily driven by the increasing incidence of chronic diseases such as autoimmune disorders, infectious diseases, and cancer, all of which often require prolonged treatment regimens.
5. The rising burden of these conditions is accelerating the adoption of home-based infusion therapies, which offer improved accessibility and operational efficiency for both patients and healthcare providers. Technological advancements, including electronic health records and portable infusion devices, further support this transition.
6. Cost efficiency remains a critical factor influencing the adoption of home infusion therapy across global healthcare systems. By facilitating intravenous treatments outside hospital settings, this model significantly reduces costs associated with inpatient care, including admissions, readmissions, and extended hospital stays.
7. Additionally, it lowers indirect expenses related to facility operations and staffing. As a result, home infusion therapy represents a financially viable alternative to traditional inpatient care for both patients and payers.

Research Methodology

1. Scope & Definitions
   • Market defined as operating revenue from home infusion therapy services
   • Includes anti-infective, chemotherapy, nutrition, hydration, immunoglobulin therapies
   • Excludes inpatient infusion and standalone device sales
   • Geography: global; Timeframe: historical + forecast period
   • MECE segmentation; “Others” ensures 100% coverage
   • Data dictionary standardizes therapy, provider, and payer definitions
   • Double counting prevented via single revenue attribution per patient episode
2. Evidence Collection (Primary + Secondary)
   • Primary interviews: providers, specialty pharmacies, clinicians, payers
   • Value chain coverage: procurement, delivery, administration, reimbursement
   • Secondary: World Health Organization, Centers for Medicare & Medicaid Services, National Home Infusion Association
   • Company filings, clinical guidelines, reimbursement databases
   • Use of verifiable sources; source-linked evidence embedded in report
3. Triangulation & Validation
   • Bottom-up: provider-level revenue aggregation
   • Top-down: healthcare expenditure allocation models
   • Cross-check with financial disclosures and payer data
   • Interview validation and conflicting-source reconciliation protocols
4. Presentation & Auditability
   • Transparent assumptions and calculation models documented
   • Source-linked citations for key insights and estimates
   • Version-controlled datasets ensuring traceability
   • Audit-ready structure enabling replication and review

Home Infusion Therapy Market Drivers

The growing adoption of advanced infusion technologies is a key factor driving market expansion.

Technological advancements are significantly improving home infusion therapy through the introduction of smart infusion pumps and advanced safety software, enhancing accuracy, safety, and operational efficiency. These innovations contribute to reducing medication errors, enabling improved patient monitoring, and ensuring seamless integration with digital healthcare systems, thereby optimizing home-based care delivery while alleviating caregiver burden.

For instance, Baxter International Inc. received U.S. FDA clearance for its Novum IQ large volume infusion pump along with Dose IQ Safety Software, strengthening its smart infusion portfolio. This development enhances patient safety and treatment efficiency, supports clinicians in managing workload pressures, and advances the adoption of connected care solutions in home infusion therapy.

The rising demand for specialized infusion services is a significant factor contributing to market growth.

The demand for specialized infusion services has increased significantly as a growing number of patients require complex, long-term treatments for chronic conditions. These services enable the delivery of customized therapies within a home setting, reducing dependence on hospital-based care. This approach supports effective management of chronic illnesses while improving patient comfort and clinical outcomes.

For instance, Dynamic Access introduced Dynamic Infusion, a specialized home infusion nursing service designed to support patients with conditions such as autoimmune disorders and multiple sclerosis. The company has also established partnerships with over 35 specialty pharmacies and conducts more than 10,000 home visits annually across multiple states, strengthening care delivery and improving patient access to specialized treatments.

Global Home Infusion Therapy Market Restraints

The home infusion therapy market faces several critical challenges that restrain its growth. A key limiting factor is the lack of awareness and understanding of home infusion therapies and their associated benefits among patients and caregivers. To enhance adoption and acceptance of home-based care models, targeted educational initiatives and outreach programs are essential to improve awareness and expand market penetration.

Global Home Infusion Therapy Market Opportunities

The rising prevalence of hospital-acquired infections, often linked to prolonged exposure to contaminated equipment, bed linens, and airborne particles, is contributing to the growth of the home infusion therapy market. This trend is encouraging a shift toward home-based treatment settings, which help minimize infection risks associated with extended hospital stays.

Additionally, continuous technological advancements, including the development of portable, lightweight, and user-friendly infusion pumps equipped with advanced drip systems, are enhancing the precision and real-time monitoring of intravenous therapies. These innovations create significant opportunities for industry participants involved in the development of advanced infusion technologies, thereby supporting overall market expansion.

How this market works end-to-end

1. Patient is diagnosed and prescribed infusion therapy
2. Eligibility assessed across adult, pediatric, or geriatric segments
3. Payer authorization defines coverage and reimbursement pathway
4. Therapy type selected based on condition and clinical protocol
5. Route of administration determined by safety and feasibility
6. Provider assigned: hospital-based, independent, or home healthcare agency
7. Specialty pharmacy sources and dispenses drugs
8. Care team schedules home visits and sets protocols
9. Infusion administered and monitored in the home
10. Claims processed across public, private, or out-of-pocket channels

Why this market matters now

The shift to home care looks simple on paper. It is not. Providers face tighter reimbursement, higher compliance risk, and uneven drug supply. Payers are more aggressive on site-of-care policies. At the same time, patient demand for home-based care is rising fast.

This creates a tension. Growth is strong, but execution risk is higher. Expanding too fast can damage margins. Moving too slow risks losing contracts and payer alignment. The real challenge is not demand. It is control—over cost, quality, and outcomes under uncertain conditions.

What matters most when evaluating claims in this market

The decision lens

1. Define therapy priorities
    Focus on therapies with stable reimbursement and manageable risk
2. Map payer exposure
    Compare public, private, and out-of-pocket dependencies
3. Stress-test provider capacity
    Check workforce, training, and geographic coverage limits
4. Validate supply reliability
    Assess drug sourcing, specialty pharmacy partnerships, and shortages
5. Analyze route economics
    Compare intravenous vs subcutaneous cost and risk profiles
6. Audit compliance readiness
    Review protocols, documentation, and home safety standards
7. Time the expansion
    Look for signals of reimbursement shifts or policy tightening

The contrarian view

Many assume home infusion is always cheaper. It is not. Poor coordination, failed visits, or compliance gaps can erase savings quickly.

Another mistake is treating all therapies the same. Chemotherapy, nutrition, and immunoglobulin therapies have very different economics and risks.

A common error is double counting revenue across providers and pharmacies. True market sizing must assign value to a single transaction layer.

Finally, scaling assumptions are often unrealistic. Workforce and logistics, not demand, limit growth.

Practical implications by stakeholder

Providers

• Must balance growth with compliance and workforce limits
• Need tighter payer alignment to protect margins

Payers

• Use site-of-care shifts to control costs
• Increase scrutiny on outcomes and billing accuracy

Specialty pharmacies

• Gain leverage in drug access and distribution
• Become central to therapy continuity

Home healthcare agencies

• Face operational complexity and training demands
• Need strong coordination with providers and payers

Patients

• Gain convenience but face variability in care quality
• Depend on provider coordination and payer approval

GLOBAL HOME INFUSION THERAPY MARKET

Home Infusion Therapy Market Segmentation

Home Infusion Therapy – By Therapy Type

• Introduction/Key Findings
• Anti-Infective Therapy
• Chemotherapy
• Parenteral Nutrition
• Hydration Therapy
• Immunoglobulin Therapy
• Pain Management Therapy
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

The anti-infective segment accounts for a significant share of market revenue, primarily due to its widespread use in administering antifungal and antibiotic therapies. Its strong preference is attributed to the high volume of procedures requiring such treatments, along with its ability to reduce patient exposure to hospital-acquired infections.

This segment continues to dominate the market, supported by the increasing incidence of bacterial, viral, and fungal infections. Patients suffering from conditions such as sepsis, osteomyelitis, and complex urinary tract infections often require extended intravenous antibiotic treatment, which is increasingly being managed in home settings. Growth is further reinforced by technological advancements and supportive reimbursement frameworks. The availability of portable infusion pumps and catheter-based delivery systems enables safe and efficient administration of anti-infective therapies at home. Additionally, reimbursement support from Centers for Medicare & Medicaid Services and private insurers is encouraging broader adoption, thereby driving segment expansion.

The chemotherapy segment is expected to witness substantial growth due to the rising prevalence of cancer and the increasing demand for more convenient treatment options. Home infusion allows patients to undergo chemotherapy in a familiar environment, reducing the need for frequent hospital visits. This segment’s growth is also driven by the cost advantages associated with home-based chemotherapy compared to inpatient care. Healthcare providers and payers are increasingly promoting this model to reduce hospital burden and improve resource utilization.

Furthermore, the chemotherapy segment is projected to be the fastest-growing segment during the forecast period, driven by the accelerating incidence of cancer. Advances in infusion technology, including compact and efficient infusion pumps designed for home use, enable accurate dosing and controlled infusion rates, ensuring safe and effective chemotherapy administration outside traditional clinical settings.

Home Infusion Therapy – By Route of Administration

• Introduction/Key Findings
• Intravenous (IV)
• Subcutaneous
• Epidural/Intrathecal
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Home infusion therapy involves the administration of drugs or biologics through intravenous or subcutaneous routes to patients in a home setting. The process requires key components, including therapeutic agents such as antivirals and immunoglobulins, equipment such as infusion pumps, and consumables including tubing and catheters. In addition, clinical oversight and proper training for patients and caregivers are essential to ensure safe and effective therapy. Visiting nurses play a critical role in monitoring treatment and supporting patients. The overall process requires coordination among multiple stakeholders, including patients, physicians, hospital discharge planners, health plans, home infusion pharmacies, and, where applicable, home healthcare agencies.

The infusion pump segment holds a substantial share of the market, driven by its expanding use beyond traditional healthcare facilities into outpatient and home settings. These devices are designed to precisely control the delivery of fluids, nutrients, and medications, thereby reducing the risk of dosing errors. Advanced infusion pumps, including smart pumps equipped with barcode technology, enhance patient identification and minimize administration errors.

Furthermore, these pumps provide real-time alerts to healthcare professionals regarding incorrect dosage selections, improving treatment safety. The market is expected to witness strong growth with the introduction of advanced systems such as the CADD-Solis ambulatory infusion pumps developed by Smiths Medical, which support efficient and reliable home-based care delivery.

Conversely, the needleless connectors segment is anticipated to experience the highest growth during the forecast period. These compact devices are used within intravenous systems to reduce the risk of needlestick injuries and prevent bacterial contamination, thereby enhancing safety standards.

IV sets serve as critical disposable components for the administration of fluids and medications, with their demand closely linked to therapy frequency and duration. Long-term treatments, such as parenteral nutrition and chronic biologic infusions, create consistent replacement cycles, supporting stable recurring revenue streams.

Innovation within this segment is focused on improving flow regulation accuracy, ensuring compatibility with smart infusion pumps, and enhancing material durability to support extended usage requirements.

Home Infusion Therapy – By Service Provider

• Introduction/Key Findings
• Hospital-Based Providers
• Independent Infusion Providers
• Home Healthcare Agencies
• Specialty Pharmacies
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Home Infusion Therapy – By Patient Type

• Introduction/Key Findings
• Adult
• Pediatric
• Geriatric
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Home Infusion Therapy – By Payer Type

• Introduction/Key Findings
• Public Insurance
• Private Insurance
• Out-of-Pocket
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Home Infusion Therapy Market Segmentation: Regional Analysis

• Introduction/Key Findings
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
• Y-O-Y Growth Trend & Opportunity Analysis

North America holds a leading position in the market, accounting for a significant share due to factors such as the rising prevalence of chronic diseases, continuous technological advancements, frequent product innovations, and high treatment costs. The burden of cancers, including bladder, colorectal, skin, and breast cancer, remains notably high in the United States, further supporting demand for infusion therapies. The region’s strong performance is also driven by cost efficiencies and improved patient mobility, which are accelerating the transition from acute care settings to home-based care models.

Asia-Pacific is expected to witness the fastest growth during the forecast period. This growth is primarily attributed to increasing patient awareness of the advantages of home infusion therapy compared to hospital-based treatments, along with the growing prevalence of diabetes across the region. Additionally, the expanding elderly population and the rising incidence of chronic diseases are anticipated to further drive market expansion in Asia-Pacific.

Latest Market News

March 2025: Medicare Payment Advisory Commission proposed payment updates for 2026, continuing support for home health services that are essential for infusion therapy delivery.

February 2025: Court Square Capital Partners completed a strategic investment in Soleo Health, which serves over 22,000 patients annually.

February 2025: Becton, Dickinson and Company announced plans to spin off its Biosciences and Diagnostic Solutions divisions to establish a focused med-tech entity centered on medication delivery and patient monitoring platforms.

January 2025: U.S. Department of Health and Human Services released its AI Strategic Plan, encouraging the responsible adoption of artificial intelligence in medical device regulation and patient care optimization.

Key Players

Baxter International Inc.

Amsino International Inc.

Contec Medical Systems, Co, Ltd

Terumo Corporation

Lepu Medical Technology

Moog Inc.

ICU Medical Inc

Smiths Medical

Option Care Health

Fresenius Kabi